Waiving IP Rights in COVID Vaccines: Reactions from Stakeholders

To curtail COVID-19’s global spread, some countries have asked the World Trade Organization to temporarily toll IP rights for coronavirus-related innovations, including COVID vaccines. But will tolling vaccine manufacturers’ IP rights adequately address access and distribution issues? Are there other solutions that might help stop the spread while taking into account the interests of IP holders?

Join us for a candid discussion with industry leaders and stakeholders where we tackle these tough questions. 

Speakers

• Bryan Nese, Partner, Intellectual Property, Mayer Brown
• Thomas Poche, Former VP and Head of IP, Allergan
• Peter Pitts, President, Center for Medicine in the Public Interest
• Cara Coburn, Associate General Counsel, Patent Law, Genentech